Brief: Relief Therapeutics Says It Remains Committed To Continuing Development Of Aviptadil

MindMaze Therapeutics Holding SA

31/05/2022 06:10

May 31 (Reuters) - RELIEF THERAPEUTICS HOLDING SA  RLFB.S :
    * RELIEF PROVIDES A CORPORATE UPDATE AND COMMENTS ON THE
RECENTLY
ANNOUNCED DSMB UPDATE ON THE U.S. NATIONAL INSTITUTES OF HEALTH
(NIH) STUDY OF INTRAVENOUS AVIPTADIL IN CRITICAL COVID-19
PATIENTS
    * RELIEF REMAINS COMMITTED TO CONTINUING DEVELOPMENT OF
AVIPTADIL
(CODENAMED RLF-100™) IN BOTH INHALED AND INTRAVENOUS
FORMULATIONS FOR OTHER INDICATIONS
    * RELIEF INTENDS TO OBTAIN AND REVIEW DATA FROM
NIH-SPONSORED
TRIAL IN ORDER TO BETTER UNDERSTAND RESULTS OBSERVED, UP TO AND
INCLUDING POINT AT WHICH STUDY WAS DISCONTINUED

Source text for Eikon:  ID:nEQ3GpSF5a 
Further company coverage:  RLFB.S 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))